Skin delivery by block copolymer nanoparticles (block copolymer micelles)

被引:15
|
作者
Laredj-Bourezg, Faiza [1 ]
Bolzinger, Marie-Alexandrine [1 ]
Pelletier, Jocelyne [1 ]
Valour, Jean-Pierre [1 ]
Rovere, Marie-Rose [2 ]
Smatti, Batoule [3 ]
Chevalier, Yves [1 ]
机构
[1] Univ Lyon 1, CNRS, Lab Automat & Genie Proc, UMR 5007, F-69622 Villeurbanne, France
[2] Univ Lyon 1, CNRS, Lab Substituts Cutanes, FRE 3310, F-69365 Lyon, France
[3] Univ Lyon 1, Ctr Imagerie Quantitat Lyon Est, F-69365 Lyon, France
关键词
Skin delivery; Cutaneous absorption; Block copolymer; Nanoparticle; METHOXY POLY(ETHYLENE GLYCOL); PLA-PEG NANOPARTICLES; PERCUTANEOUS-ABSORPTION; DRUG-DELIVERY; POLYMERIC MICELLES; TOPICAL DELIVERY; PENETRATION; SURFACTANTS; OXIDE); CORE;
D O I
10.1016/j.ijpharm.2015.11.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Block copolymer nanoparticles often referred to as "block copolymer micelles" have been assessed as carriers for skin delivery of hydrophobic drugs. Such carriers are based on organic biocompatible and biodegradable materials loaded with hydrophobic drugs: poly(lactide)-block-poly(ethylene glycol) copolymer(PLA-b-PEG) nanoparticles that have a solid hydrophobic core made of glassy poly(D,L-lactide), and poly(caprolactone)-block-poly(ethylene glycol) copolymer (PCL-b-PEG) nanoparticles having a liquid core of polycaprolactone. In vitro skin absorption of all-trans retinol showed a large accumulation of retinol in stratum corneum from both block copolymer nanoparticles, higher by a factor 20 than Polysorbate 80 surfactant micelles and by a factor 80 than oil solution. Additionally, skin absorption from PLA-b-PEG nanoparticles was higher by one order of magnitude than PCL-b-PEG, although their sizes (65 nm) and external surface (water-swollen PEG layer) were identical as revealed by detailed structural characterizations. Fluorescence microscopy of histological skin sections provided a non-destructive picture of the storage of Nile Red inside stratum corneum, epidermis and dermis. Though particle cores had a different physical states (solid or liquid as measured by H-1 NMR), the ability of nanoparticles for solubilization of the drug assessed from their Hildebrand solubility parameters appeared the parameter of best relevance regarding skin absorption. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:1034 / 1046
页数:13
相关论文
共 50 条
  • [1] Mineralization of nanoparticles in block copolymer micelles
    Moller, M
    Spatz, JP
    CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 1997, 2 (02) : 177 - 187
  • [2] Amphiphilic Block Copolymer Micelles for Gene Delivery
    Li Qin
    Jin Bixin
    Luo Yunjun
    Li Xiaoyu
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2022, 38 (06) : 1368 - 1379
  • [3] Amphiphilic Block Copolymer Micelles for Gene Delivery
    Qin Li
    Bixin Jin
    Yunjun Luo
    Xiaoyu Li
    Chemical Research in Chinese Universities, 2022, 38 : 1368 - 1379
  • [4] Block copolymer micelles as drug delivery systems
    Kwon, GS
    ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (02) : 167 - 167
  • [5] Block copolymer micelles
    Gohy, JF
    BLOCK COPOLYMERS II, 2005, 190 : 65 - 136
  • [6] Magnetic nanoparticles in block copolymer micelles.
    Bronstein, LM
    Kostylev, M
    Remmes, NB
    Baxter, DV
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U827 - U827
  • [7] Characterization of nanoparticles based on block copolymer micelles
    Plestil, J
    Pospísil, H
    Kríz, J
    Kadlec, P
    Tuzar, Z
    Cubitt, R
    LANGMUIR, 2001, 17 (21) : 6699 - 6704
  • [8] Block copolymer micelles for the encapsulation and delivery of amphotericin B
    Lavasanifar, A
    Samuel, J
    Sattari, S
    Kwon, GS
    PHARMACEUTICAL RESEARCH, 2002, 19 (04) : 418 - 422
  • [9] Block copolymer micelles as ocular drug delivery systems
    Assiri, Ahmad A.
    Glover, Katie
    Mishra, Deepakkumar
    Waite, David
    Vora, Lalitkumar K.
    Thakur, Raghu Raj Singh
    DRUG DISCOVERY TODAY, 2024, 29 (08)
  • [10] Block copolymer micelles as a solution for drug delivery problems
    Torchilin, VP
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (01) : 63 - 75